Volume 4 Number 10 December 2003/January 2004 PDF

Volume 4 Number 10 December 2003

9th European AIDS Conference (EACS), 25-29 October 2003, Warsaw

Lower doses of d4T produce similar efficacy and reduced side effects

Switching from efavirenz to nevirapine to avoid CNS side effects

Interruption of treatment is safe for those who started too early

T20 is cost effective for UK purchasers

Intrauterine exposure to efavirenz

African patients and adherence in the UK

Five-year results of Kaletra-based therapy in treatment-naïve HIV patients

IL-2 effectively increases CD4 count in people with low CD4 nadir

Hepatitis coinfection: incidence in Europe and response to transplant

Rituximab plus CDE for HIV-related Non-Hodgkins Lymphoma (NHL)

Access to treatment – some progress…

WHO approves combination pills

South African Competition Commission finds GSK and BI responsible for ‘excessive pricing’ and ‘abuse of market position’

FTC (emtricitabine, Emtriva) approved in Europe

EMEA recommend approval for atazanavir for treatment experienced patients

Fosamprenavir (Lexiva) approved in US

Polylactic acid (New-gill) repairs facial wasting and improves quality of life

US paediatric, adult and maternal-child guidelines updated

Increased risk of myocardial infarction associated with duration of protease inhibitor treatment

UK guidelines for treating coinfection with HIV and hepatitis B or C published online

Kidney and liver transplantation in HIV-infected patients: case presentations and review

London epidemic of sexually transmitted hepatitis C

Dramatic decline in mortality, disease progression and hospital admissions in children with HIV infection in the UK and Ireland

New tool for assessing risks of disease progression and death based on age, CD4 percentage and viral load in HIV-infected children

VaxGen AIDSVAX vaccine fails in Thailand

Access to HIV treatment in Eastern Europe


Online medical lectures

Newsletters and reports

HIV and hepatitis coinfection

Other news

Volume 4 Number 9 November 2003

Important safety information: high rate of virologic failure in patients with HIV infection treated with a once-daily triple NRTI combination containing ddI, 3TC, and tenofovir DF

13th International Conference on AIDS and STIs in Africa (ICASA), 21-26 September 2003, Nairobi

STIs in resource limited settings

43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14-17 September 2003, Chicago

ddI may retain activity in nucleoside experienced patients

Studies and strategies with existing drugs

Incremental progress with new antiviral drugs

Newer nucleoside analogues show fewer adverse effects

Interaction between amprenavir and lopinavir thwarts triple PI salvage

Vitamin C induces P4503A4 and reduces indinavir levels

Indinavir levels reduced by omeprazole

Boosted saquinavir PK in once-daily regimes

Tenofovir drug-drug interactions

Summary of other PK studies

Global AIDS spending must double by 2005, says gloomy UN

GARPP requests permission from Boehringer to import generic nevirapine

Canada decides to lead the way in exempting AIDS drugs from patent laws

Atazanavir ‘named-patient’ access extended in the UK and includes 150mg capsule

Another triple nuke failure: abacavir/ddI/d4T

FDA announces changes to ritonavir package insert

Treatment interruption prior to five-drug regime shows no benefit at 48 weeks

Failure of alternating week-on and week-off therapy

Canadian study shows increased interventional cardiovascular procedures associated with HAART

Valacyclovir is effective prophylaxis against herpes simplex

Antiviral dynamics and sex differences of AZT and 3TC triphosphate concentrations

Women have a greater immunological response to effective HAART

Use of rapid HIV tests in labour

Eighteen-month findings of HIVNET 012

Rituximab as single agent reversed paediatric Non-Hodgkins Lymphoma (NHL)

Perinatal antiretroviral treatment and haematopoiesis in HIV-uninfected infants

Post navigation